# Regulatory submission
> A regulatory submission is the formal dossier sent to a health authority to seek approval for a medicine, indication, formulation or regulated change, supported by quality, safety and efficacy evidence.
Source: https://www.visfo.health/glossary/regulatory-submission
Updated: 2026-08-16T21:55:00.604939+00:00

What is a regulatory submission?
A regulatory submission is the formal dossier sent to a health authority to seek approval for a new medicine, indication, formulation or other regulated change. It contains the clinical, non-clinical and manufacturing evidence needed for the authority to assess the product’s quality, safety, efficacy and benefit–risk profile.

Submissions are made to agencies such as the FDA, EMA or PMDA. Their exact content depends on the application and jurisdiction, but may include administrative information, scientific summaries, study reports, manufacturing and quality data, proposed product information, risk management plans and responses to agency requirements.

Why does a regulatory submission matter in regulatory affairs?
The submission is a critical milestone between generating evidence and receiving permission to market or change a medicine. Its quality, clarity and completeness affect how efficiently reviewers can assess the application. Gaps, inconsistencies or poorly supported claims can lead to questions, requests for further analysis or delays to the planned [launch](/launch).

It also creates the approved regulatory foundation for product labelling and external claims. Those decisions influence later work by [medical affairs](/glossary/medical-affairs), commercial and [market access](/glossary/market-access) teams. Early cross-functional planning is therefore needed to align the evidence, target product profile and proposed wording.

How is a regulatory submission prepared and run in practice?
Regulatory affairs usually develops the submission strategy, confirms agency requirements and coordinates the overall dossier. Clinical, safety, non-clinical, statistics, manufacturing, quality, medical writing, publishing and legal or compliance specialists contribute source material and review relevant sections.

The work commonly includes:
- defining the intended approval, claims and submission route;
- mapping available evidence against applicable requirements and identifying gaps;
- agreeing document ownership, data cut-offs, dependencies and review timelines;
- writing summaries that remain consistent with underlying reports and datasets;
- checking terminology, references, product details and conclusions across documents;
- formatting, validating and publishing the dossier in the required electronic structure;
- submitting it, tracking agency questions and coordinating responses throughout review.

Document control and traceability are important because one change may affect several sections. Teams need a controlled source of truth, clear approval responsibilities and enough time for scientific review rather than treating publishing as the final administrative step.

What does a regulatory submission contain?
Many applications use the Common Technical Document structure or a related electronic format. The dossier brings together regional administrative material and scientific information covering quality, non-clinical and clinical evidence. Depending on the product and application, it can also include safety updates, statistical outputs, manufacturing validation, proposed labelling, pharmacovigilance arrangements and risk management measures.

Not every submission is a full application for a new product. Authorities also receive submissions for new indications, line extensions, manufacturing changes, safety updates and post-approval commitments. The required evidence is determined by the regulatory question being asked, the product’s history and the relevant authority’s procedures.

Who owns a regulatory submission, and where do teams go wrong?
Regulatory affairs normally owns the submission strategy and authority relationship, but no single function owns all its evidence. Accountable contributors must verify that their sections are accurate, current and consistent with the proposed claims. Senior governance may be needed where evidence limitations or benefit–risk decisions affect the filing strategy.

Common problems include starting dossier planning too late, treating individual sections as standalone documents, using inconsistent data or terminology, and failing to connect claims to supporting evidence. Teams can also underestimate the work required after filing. Agency questions often require rapid input from the same experts who developed the original analyses, so response planning should begin before submission.

How does a regulatory submission differ from the dossiers used for access decisions?
A regulatory submission asks whether a medicine meets the authority’s requirements for approval and defines the conditions under which it may be marketed. A [health technology assessment](/glossary/health-technology-assessment-hta) considers questions such as comparative clinical benefit, cost effectiveness and value within a health system. A global value dossier supports consistent communication of the product’s value evidence but is not itself an application for marketing authorisation.

These materials may draw on overlapping studies, yet they serve different decision-makers and must not be treated as interchangeable. Regulatory approval establishes the authorised product and claims; access dossiers then support decisions about assessment, funding, price and use in practice.